Navigation Links
Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
Date:11/10/2009

Current focus on COPD and Immuno-Therapeutic Cancer Treatment

San Diego, CA (PRWEB) November 10, 2009 -- Entest BioMedical, Inc. (OTCBB: ENTB) discussed its current therapies in development in the areas of immuno-therapeutic treatment of cancer and Chronic Obstructive Pulmonary Disease (COPD) and their potential to generate significant revenue for the Company.

1.   Immuno-therapeutic treatment of cancer – The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. The Company’s initial goal is to treat 2,000 dogs at $3,000 per dog (yielding $6,000,000 in revenue) and believes revenue could begin to be generated within the next 9 months. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

2.   Entest has applied for a contract with the National Cancer Institute (NCI) for the initial development of an immuno-therapeutic cancer drug. This contract, if awarded to Entest, will have a value of $200,000 and will cover Phase I clinical evaluation. If the drug demonstrates reasonable efficacy, NCI may coordinate and fund further development through Phases II and III, with the ultimate goal being commercialization of the drug in partnership with NCI.

3.   COPD –There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms. The Company foresees substantial revenue in treating COPD and is currently in discussions with several entities regarding possible joint ventures involving the Company’s developing patent pending treatment.

Entest anticipates funding a significant amount of its research development costs by obtaining grant funding. The Company is in the process of applying for $3 million of federal grant funding for both COPD treatment and immuno-therapeutic treatment of cancer.

About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:

David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
www.EntestBio.com

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3181314.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
2. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
3. Interview with Dr. Elisabeth Hager, CEO of Balan Biomedical, Inc., to Air Nationally on Sky Radio
4. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
5. In Case You Missed It: Landrieu Discusses Health Care Reform on MSNBC
6. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
7. Karmanos Chief Cancer Surveillance Researcher Discusses Study on Decreased Cancer Mortality Rates
8. Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates
9. The Caryl Ehrlich Program Discusses Food Addiction on HealthyPlace.com
10. Natural Healers Discusses How Personal Trainer Certification May Be Changing in Some States
11. Natural Healers Discusses How Alternative Medicine Careers Provide a Little 'Wellness' in a Tough Economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The ... Drug Development through Molecular Imaging.” The focus of ADDMI-IG will be geared towards ... and development pipeline issues. Through ADDMI-IG WMIS will provide a platform for productive ...
(Date:5/25/2016)... Miami, FL (PRWEB) , ... May 25, 2016 , ... ... deep dive into the unique integrative medical wellness offerings of Europe, a continent that ... in Tyrol, Austria will hear from numerous pioneers in medical wellness, including Henri Chenot, ...
(Date:5/25/2016)... ... ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, introduces a ... wellness suites . The two 1,350 sq. ft. suites which debuted in late 2015 ... amenities, from a custom soap selection and in-suite exercise kit to a personal wellness ...
(Date:5/25/2016)... ... May 25, 2016 , ... America Walks , a ... M.S.L., M.S.P.A., of the University of Pittsburgh Graduate School of Public Health , ... Ms. Reichbaum and 24 other advocates from around the country to participate in a ...
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows users to ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... add stylish color grades to their footage. A LUT is a Lookup Table that ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/24/2016)... , May 24, 2016 ... elkaar verbindt, zodat zij collectief patiënten kunnen behandelen, hun ... is het idee achter de nieuwe en revolutionaire MDLinking ... van de Nederlandse vaatchirurg dr. Hans Flu en oncologisch ... app, die inmiddels beschikbaar is, wordt op dinsdag 24 ...
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
Breaking Medicine Technology: